This week the US Food and Drug Administration approved the release of fingolimod (trade name Gilenya®), the first oral medication for the treatment of remitting relapsing multiple sclerosis. Swedish Neuroscience Institute is proud to have participated in the pivotal clinical trial that led to the approval of Gilenya. Gilenya is a welcome addition to the set of medications available to patients living with MS. There are currently five injectable therapies and two intravenous therapies approved by the FDA for the treatment of MS. Although these treatments are very effective, many patients have been hoping for an oral alternative. Some patients are finding that they have “injection fatigue” or are running out of places to inject the medication. It is important to note, however, that not all patients should switch to Gilenya. Patients with stable disease should remain on their medications. Patients need to be informed of the risks associated with Gilenya, including slowed heart rate, increased blood pressure, difficulty breathing, abnormal liver function, and infection, and how these risks may apply to them. If you are wondering whether Gilenya is right for you, please ask your neurologist.
Most Recent Articles
Harmony Hill: Inspiring Healthy Living for All and Transforming the Lives of Those Affected by Cancer
When it comes resolutions, small changes are best
A journey to a healthier you starts with baby steps. Discover how to set yourself up for success this new year and in months to come.
HPV vaccine and regular screenings can reduce cervical cancer risk
January is Cervical Health Awareness Month. Protect your health by staying current with recommended cancer screenings.
2020: The year of little sleep
This year has seen an increase in sleep issues and stress-induced insomnia. Dr. Darius Zoroufy at Swedish Sleep Medicine gives you tips to get the sleep you need.
Virtual reality adventures for people with MS
Learn about an addition to the Adventure Program offered at the Swedish Multiple Sclerosis Center that features virtual reality activities and locations.
Celebrating the holidays safely during COVID-19
Swedish shares tips and guidance from the CDC and local health officials to help you celebrate the holidays safely despite the COVID-19 pandemic.
World AIDS Day goes virtual
Virtual events and activities mark the annual observance of World AIDS Day, which focuses on learning from the past to plan for the future.
A new ride for rehabilitation
Learn how the Alinker bike will help patients have a better experience in rehabilitation for neurological conditions, age-related issues, and even COVID-19.
Hope for patients with ALS
Groundbreaking clinical trial update in the treatment and holistic care of ALS patients.
Reducing prematurity rates with equal access and care for all
The numbers of babies born too soon have steadily risen over the past few years, particularly among women of color. Access to care can help.
Is inflammation speeding up your aging process?
Long term inflammation can lead to many chronic conditions like diabetes, heart disease or arthritis, as you grow older. Find out more.
Pancreatic cancer doesn’t always show symptoms right away
Pancreatic cancer is not a common type of cancer, but it can be serious. Learn the signs, risk factors and how exercise can impact outcomes.
Understand your risk of diabetes
Diabetes is a common but serious chronic health condition. Read about your diabetes risk and how to manage your good health.
Coping with the holidays, COVID-19 and winter blues
Boost your mental wellness as we head into the holidays, winter weather and continue COVID-19 precautions with these simple tips.
